Joanna Marta Wasielewska

Mrs. Joanna Marta Wasielewska

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
GBGabriel Berdugo-Vega
Gabriel Berdugo-Vega
GAGonzalo Arias-Gil
Gonzalo Arias-Gil
ALAdrian López-Fernández
Adrian López-Fernández
BABenedetta Artegiani
Benedetta Artegiani
JWJoanna Marta Wasielewska
Joanna Marta Wasielewska
FCFederico Calegari
Federico Calegari
Functional plasticity of the brain decreases during ageing causing marked deficits in contextual learning, allocentric navigation and episodic memory. Adult neurogenesis is a prime example of hippocampal plasticity promoting the contextualisation of information and dramatically decreases during ageing. We found that a genetically-driven expansion of neural stem cells by overexpression of the cell cycle regulators Cdk4/cyclinD1 compensated the age-related decline in neurogenesis. This triggered an overall inhibitory effect on the trisynaptic hippocampal circuit resulting in a changed profile of CA1 sharp-wave ripples known to underlie memory consolidation. Most importantly, increased neurogenesis rescued the age-related switch from hippocampal to striatal learning strategies by rescuing allocentric navigation and contextual memory. Our study demonstrates that critical aspects of hippocampal function can be reversed in old age, or compensated throughout life, by exploiting the brain’s endogenous reserve of neural stem cells.

7 March 2022 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
JWJoanna Marta Wasielewska
Joanna Marta Wasielewska
Anthony R. WhiteAnthony R. White
Anthony R. White
The blood-brain barrier (BBB) has a major protective function in preventing the entry of harmful molecules into the brain, but is simultaneously limiting the delivery of drugs, restricting their potential clinical application in neurodegenerative diseases. Recent preclinical evidence demonstrates that following application of focused ultrasound with microbubbles (FUS+MB), the BBB becomes reversibly accessible to compounds that normally are brain-impermeable, suggesting FUS+MB as a promising new platform for delivery of therapeutic agents into the central nervous system. As a step towards translation, small cohort clinical studies were performed demonstrating safe BBB opening in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS) patients following FUS+MB, however improved drug delivery has not yet been achieved in human. Simultaneously, rapid progress in the human induced pluripotent stem cell (hiPSC) modeling technology allowed for development of novel Alzheimer’s disease patient-derived BBB in vitro model that reacts to FUS+MB with BBB opening and can be used to answer fundamental questions of human BBB responses to FUS+MB in health and disease. This review summarizes key features of the BBB that contribute to limited drug delivery, recapitulates recent advances in the FUS+MB mediated human BBB opening in vivo and in vitro in the context of neurodegenerative disorders, and highlights potential strategies for fast-track translation of the FUS+MB to improve bioavailability of drugs to the human brain. With safe and effective application, this innovative FUS+MB technology may open new avenues for therapeutic interventions in neurodegenerative diseases leading to improved clinical outcomes for patients.

Verified
Journal Article
Open access
PDF file
XCXin Yi Choo
Xin Yi Choo
LMLachlan E. McInnes
Lachlan E. McInnes
AGAlexandra Grubman
Alexandra Grubman
JWJoanna Marta Wasielewska
Joanna Marta Wasielewska
IBIrina Belaya
Irina Belaya
Anthony R. WhiteAnthony R. White
Anthony R. White
Neuroinflammation has a major role in several brain disorders including Alzheimer’s disease (AD), yet at present there are no effective anti-neuroinflammatory therapeutics available. Copper(II) complexes of bis(thiosemicarbazones) (CuII(gtsm) and CuII(atsm)) have broad therapeutic actions in preclinical models of neurodegeneration, with CuII(atsm) demonstrating beneficial outcomes on neuroinflammatory markers in vitro and in vivo. These findings suggest that copper(II) complexes could be harnessed as a new approach to modulate immune function in neurodegenerative diseases. In this study, we examined the anti-neuroinflammatory action of several low-molecular-weight, charge-neutral and lipophilic copper(II) complexes. Our analysis revealed that one compound, a thiosemicarbazone–pyridylhydrazone copper(II) complex (CuL5), delivered copper into cells in vitro and increased the concentration of copper in the brain in vivo. In a primary murine microglia culture, CuL5 was shown to decrease secretion of pro-inflammatory cytokine macrophage chemoattractant protein 1 (MCP-1) and expression of tumor necrosis factor alpha (Tnf), increase expression of metallothionein (Mt1), and modulate expression of Alzheimer’s disease-associated risk genes, Trem2 and Cd33. CuL5 also improved the phagocytic function of microglia in vitro. In 5xFAD model AD mice, treatment with CuL5 led to an improved performance in a spatial working memory test, while, interestingly, increased accumulation of amyloid plaques in treated mice. These findings demonstrate that CuL5 can induce anti-neuroinflammatory effects in vitro and provide selective benefit in vivo. The outcomes provide further support for the development of copper-based compounds to modulate neuroinflammation in brain diseases.

13 March 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
JWJoanna Marta Wasielewska
Joanna Marta Wasielewska
KSKathryn Szostak
Kathryn Szostak
LMLachlan E. McInnes
Lachlan E. McInnes
HQHazel Quek
Hazel Quek
JCJuliana C. S. Chaves
Juliana C. S. Chaves
Anthony R. WhiteAnthony R. White
Anthony R. White

25 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
GBGabriel Berdugo-Vega
Gabriel Berdugo-Vega
GAGonzalo Arias-Gil
Gonzalo Arias-Gil
ALAdrian López-Fernández
Adrian López-Fernández
BABenedetta Artegiani
Benedetta Artegiani
JWJoanna Marta Wasielewska
Joanna Marta Wasielewska
FCFederico Calegari
Federico Calegari
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

1 January 2024 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Open access
Angus WeekesAngus Weekes
Angus Weekes
JWJoanna Marta Wasielewska
Joanna Marta Wasielewska
NPNigel Pinto
Nigel Pinto
JJJason Jenkins
Jason Jenkins
JPJatin Patel
Jatin Patel
Christoph MeinertChristoph Meinert
Christoph Meinert
Tissue engineering is a promising approach for the production of small‐diameter vascular grafts; however, there are limited data directly comparing the suitability of applicable cell types for vessel biofabrication. Here, we investigated the potential of adult smooth muscle cells (SMCs), placental mesenchymal stem cells (MSCs), placental endothelial colony‐forming cells (ECFCs), and a combination of MSCs and ECFCs on highly porous biocompatible poly(ɛ‐caprolactone) (PCL) scaffolds produced via melt electrowriting (MEW) for the biofabrication of tissue‐engineered vascular grafts (TEVGs). Cellular attachment, proliferation, and deposition of essential extracellular matrix (ECM) components were analysed in vitro over four weeks. TEVGs cultured with MSCs accumulated the highest levels of collagenous components within a dense ECM, while SMCs and the coculture were more sparsely populated, ascertained via histological and immunofluorescence imaging, and biochemical assessment. Scanning electron microscopy (SEM) enabled visualisation of morphological differences in cell attachment and growth, with MSCs and SMCs infiltrating and covering scaffolds completely within the 28‐day culture period. Coverage and matrix deposition by ECFCs was limited. However, ECFCs lined the ECM formed by MSCs in coculture, visualised via immunostaining. Thus, of cells investigated, placental MSCs were identified as the preferred cell source for the fabrication of tissue‐engineered constructs, exhibiting extensive population of porous polymer scaffolds and production of ECM components; with the inclusion of ECFCs for luminal endothelialisation, an encouraging outcome warranting further consideration in future studies. In combination, these findings represent a substantial step toward the development of the next generation of small‐diameter vascular grafts in the management of cardiovascular disease.